Grand Pharma Sustainability Profile
Grand Pharma (also known as Grand Pharmaceutical Group Limited) is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1998, the company has made significant strides in the development, manufacturing, and distribution of innovative healthcare solutions across various operational regions, including Asia and beyond. Specialising in prescription drugs, over-the-counter medications, and active pharmaceutical ingredients, Grand Pharma distinguishes itself through its commitment to quality and research-driven approaches. The company has achieved notable milestones, including strategic partnerships and a robust portfolio of unique products that cater to diverse therapeutic areas. With a strong market position, Grand Pharma is recognised for its contributions to healthcare, consistently striving to enhance patient outcomes and expand its global footprint.
DitchCarbon Score
How does Grand Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grand Pharma's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grand Pharma's reported carbon emissions
In 2021, Grand Pharma reported significant carbon emissions, totalling approximately 172,000,000 kg CO2e for Scope 1 and about 104,000,000 kg CO2e for Scope 2. This data is cascaded from its parent company, Grand Pharmaceutical (China) Co., Ltd., reflecting the organisation's operational impact on global carbon emissions. Currently, Grand Pharma has not established specific reduction targets or initiatives, nor does it disclose any Scope 3 emissions data. The absence of defined climate pledges or Science-Based Targets Initiative (SBTi) commitments indicates a potential area for future development in their climate strategy. As a current subsidiary, Grand Pharma's emissions data and climate commitments are aligned with the broader industry context, where many companies are increasingly focusing on reducing their carbon footprints and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 172,000,000 |
| Scope 2 | 104,000,000 |
| Scope 3 | - |
How Carbon Intensive is Grand Pharma's Industry?
How Carbon Intensive is Grand Pharma's Location?
Grand Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Grand Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
